<DOC>
	<DOCNO>NCT01100034</DOCNO>
	<brief_summary>Psoriasis chronic , often severe , autoimmune condition affect approximately 2 % world 's population . The epidemiology pediatric psoriasis well document treatment guideline exist pediatric psoriasis . Etanercept biologic drug license treatment chronic severe plaque psoriasis child adolescent ( 8-17 year age ) inadequately control intolerant , systemic therapy phototherapy . Although long-term safety efficacy etanercept child juvenile idiopathic arthritis ( JIA ) study short-term safety profile etanercept JIA pediatric psoriasis appear similar , limited data available long-term effect etanercept pediatric psoriasis , especially respect malignancy . The aim study assess safety effectiveness etanercept treatment pediatric psoriasis Europe . Patients age 4-17 plaque psoriasis diagnose dermatologist invited participate registry clinical decision make prescribe etanercept . The safety drug well drug work evaluate follow-up period . The follow-up period last 5 year patient follow every 3 month first 2 year every 6 month next 3 year .</brief_summary>
	<brief_title>Study Evaluating Safety Effectiveness Etanercept Treatment Pediatric Psoriasis</brief_title>
	<detailed_description>Non-probability sample</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>17 year age young Diagnosed plaque psoriasis dermatologist . Prior enrollment , must clinical decision initiate etanercept treatment plaque psoriasis etanercept must initiate . Actively treated etanercept , regardless length treatment prior enrollment Willing provide write informed consent Prior therapy etanercept biologic agent History malignancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pediatric psoriasis</keyword>
	<keyword>etanercept</keyword>
	<keyword>PASS</keyword>
	<keyword>safety</keyword>
	<keyword>effectiveness</keyword>
</DOC>